Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1

Targeting the HIV-1 spike and co-receptor with bi- and trispecific antibodies for single-component broad inhibition of entry

(2018) Salar N Khan et al.   JOURNAL OF VIROLOGY

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity

(2018) James J. Steinhardt et al.   Nature Communications

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections

(2018) Kshitij Wagh et al.   PLoS Pathogens

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

(2018) Pilar Mendoza et al.   NATURE

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

(2018) Yotam Bar-On et al.   NATURE MEDICINE

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

(2018) Brinda Emu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies

(2018) Matthew S. Parsons et al.   Retrovirology

Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys

(2017) Boris Julg et al.   JOURNAL OF VIROLOGY

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

(2017) Ling Xu et al.   SCIENCE

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

(2017) Boris Julg et al.   Science Translational Medicine

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

(2017) Boris Julg et al.   Science Translational Medicine

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

(2016) Stylianos Bournazos et al.   CELL

Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity

(2016) Yaoxing Huang et al.   CELL

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

(2016) Jinghe Huang et al.   IMMUNITY

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies

(2016) Ruijiang Song et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo

(2016) Maud Deruaz et al.   JOURNAL OF INFECTIOUS DISEASES

Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies

(2016) Hannah M. Cheeseman et al.   JOURNAL OF VIROLOGY

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

(2016) Johannes F. Scheid et al.   NATURE

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

(2016) Ann J Hessell et al.   NATURE MEDICINE

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

(2016) Katharine J. Bar et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

(2016) T. Schoofs et al.   SCIENCE

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

(2016) C.-L. Lu et al.   SCIENCE

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

(2016) Kshitij Wagh et al.   PLoS Pathogens

Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization

(2015) M. Asokan et al.   JOURNAL OF VIROLOGY

Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection

(2015) Kevin O. Saunders et al.   JOURNAL OF VIROLOGY

A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype BenvGene

(2015) Pavel Pugach et al.   JOURNAL OF VIROLOGY

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

(2015) Kevin O. Saunders et al.   JOURNAL OF VIROLOGY

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

(2015) Nicole A. Doria-Rose et al.   JOURNAL OF VIROLOGY

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

(2015) Marina Caskey et al.   NATURE

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

(2015) Rebecca M. Lynch et al.   Science Translational Medicine

Env–2dCD4S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1)

(2015) Mark A. Killick et al.   VACCINE

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike

(2015) Jeong Hyun Lee et al.   Nature Communications

Generation and Characterization of an HIV-1 Subtype C Transmitted and Early Founder Virus Consensus Sequence

(2014) Mark Killick et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity

(2014) Stylianos Bournazos et al.   CELL

Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers

(2014) Claudia Blattner et al.   IMMUNITY

Rational Design and Characterization of the Novel, Broad and Potent Bispecific HIV-1 Neutralizing Antibody iMabm36

(2014) Ming Sun et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Disulfide Reduction in CD4 Domain 1 or 2 Is Essential for Interaction with HIV Glycoprotein 120 (gp120), which Impairs Thioredoxin-driven CD4 Dimerization

(2014) Nichole Cerutti et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes

(2014) Rui Kong et al.   JOURNAL OF VIROLOGY

Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo

(2014) R. S. Rudicell et al.   JOURNAL OF VIROLOGY

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

(2014) Sung-Youl Ko et al.   NATURE

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

(2014) Nicole A. Doria-Rose et al.   NATURE

Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission

(2014) Alejandro B Balazs et al.   NATURE MEDICINE

Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

(2013) A. deCamp et al.   JOURNAL OF VIROLOGY

Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1

(2013) C. S. Pace et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dual targeting strategies with bispecific antibodies

(2012) Roland Kontermann   mAbs

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

(2012) Jinghe Huang et al.   NATURE

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

(2012) Florian Klein et al.   NATURE

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

(2012) B. Moldt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Construction and Phenotypic Characterization of HIV Type 1 Functional Envelope Clones of Subtypes G and F

(2011) Ana Revilla et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Genetic and Neutralization Sensitivity of Diverse HIV-1envClones from Chronically Infected Patients in China

(2011) Hong Shang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antibody-based protection against HIV infection by vectored immunoprophylaxis

(2011) Alejandro B. Balazs et al.   NATURE

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

(2011) R. Pejchal et al.   SCIENCE

Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients

(2010) R. Song et al.   JOURNAL OF VIROLOGY

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody

(2010) Michael M. Freeman et al.   STRUCTURE

Evidence that Ecotropic Murine Leukemia Virus Contamination in TZM-bl Cells Does Not Affect the Outcome of Neutralizing Antibody Assays with Human Immunodeficiency Virus Type 1

(2009) E. J. Platt et al.   JOURNAL OF VIROLOGY

Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies

(2009) M. S. Seaman et al.   JOURNAL OF VIROLOGY

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

(2009) Leonidas Stamatatos et al.   NATURE MEDICINE

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

(2009) Ann J Hessell et al.   NATURE MEDICINE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India

(2009) Smita S. Kulkarni et al.   VIROLOGY

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

(2009) Ann J. Hessell et al.   PLoS Pathogens

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

(2008) J. M. Jacobson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identification of Gammaretroviruses Constitutively Released from Cell Lines Used for Human Immunodeficiency Virus Research

(2008) Y. Takeuchi et al.   JOURNAL OF VIROLOGY